Findings
TOMs are underutilized in clinical trials for neurodegenerative disorders.
Challenges include relevance of measured targets, standardization of parameters, costs, and patient compliance.
Lack of validation studies for TOMs’ clinical meaningfulness and issues with proprietary platform integration.

Recommendations
Validate TOMs output to ensure clinical meaningfulness.
Standardize clinically relevant measures and procedures.
Establish a single platform for data integration from various proprietary platforms.
Assist in regulatory approvals to facilitate wider use of TOMs.
Enhance the ecological validity of TOMs by using them in natural settings.

Regulatory Considerations
Overcome regulatory roadblocks for wider use of TOMs.
Assist manufacturers in obtaining regulatory approvals for TOMs.
Address integration issues with proprietary platforms from different manufacturers.